Cardiovascular Research

What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining i

Authors: E R Schwarz|||Y Somoano|||S L Hale|||R A Kloner

Affiliations: + Expand

Abstract

Measurements of infarct size by use of tripenyltetrazoliumchloride (TTC) is a widely accepted method used to delineate the extent of myocardial necrosis following coronary occlusion and reperfusion in various animal experiments. There is controversy, however, regarding the optimal reperfusion time for estimating the maximally infarcted area by TTC staining in the rat. We tested six different reperfusion times following 90 minutes of regional myocardial ischemia. Group 1 had 5 minutes of reperfusion (n=6), group 2 had 30 minutes of reperfusion (n=6), group 3 had 1 hour of reperfusion (n=6), group 4 had 2 hours of reperfusion (n=6), group 5 had 3 hours of reperfusion (n=6), group 6 had 4.5 hours of reperfusion (n=6). Risk areas, measured by the use of blue dye, were similar among the 6 study groups. Infarct size as a percent of risk area was 57+/-11% in group 1, 74+/-7% in group 2, 61+/-9% in group 3, 71+/-5% in group 4, 70+/-5% in group 5, and 64+/-9% in group 6 (x+/-standard error [SE]). There was no significant difference in infarct size between the groups. However, prior to 60 minutes of reperfusion, patches of pink and white areas were observed within the risk regions, indicating a more difficult assessment of proper delineation of outer regions of necrotic tissue. For acute assessment of infarct size, reperfusion for 60 minutes or more is optimal because the infarct does appear homogeneous at that time and does not become larger with longer reperfusion periods.

---

Chemical List

Coloring Agents|||Tetrazolium Salts|||Formaldehyde|||triphenyltetrazolium

---

Reference List

Am J Physiol. 1992 Oct;263(4 Pt 2):H1107-12|||Cardiovasc Res. 1992 Mar;26(3):226-31|||J Cardiovasc Pharmacol. 1995 Jan;25(1):163-7|||Pharmacology. 1994 Nov;49(5):319-24|||J Mol Cell Cardiol. 1997 Feb;29(2):657-66|||Am J Pathol. 1985 Dec;121(3):522-30|||Can J Cardiol. 1996 May;12(5):517-21|||J Cardiovasc Pharmacol. 1994 Jun;23(6):922-31|||Basic Res Cardiol. 1995 Sep-Oct;90(5):404-9|||Cardiovasc Res. 1993 Apr;27(4):608-11|||Am Heart J. 1994 Apr;127(4 Pt 1):779-85|||J Mol Cell Cardiol. 1995 Sep;27(9):1883-94|||Eur J Pharmacol. 1995 Jun 12;279(2-3):251-6|||Cardiovasc Res. 1995 Dec;30(6):945-51|||Am J Physiol. 1994 Feb;266(2 Pt 2):H829-39|||Cardiovasc Res. 1995 Dec;30(6):1033-7|||Z Kreislaufforsch. 1959 Sep;48:802-9|||Cardiovasc Res. 1992 Oct;26(10):983-7|||Cardiovasc Res. 1993 Apr;27(4):551-5|||Am J Cardiol. 1995 Aug 24;76(6):41B-44B|||Br J Pharmacol. 1994 Nov;113(3):869-76|||Circulation. 1995 Aug 15;92(4):912-7